Reducing tobacco addiction through tobacco product regulation
- 1Pinney Associates Inc, Bethesda, Maryland, USA and Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 2University of California San Francisco, San Francisco, California, USA
- 3Harvard University School of Public Health, Boston, Massachusetts, USA
- 4Henry Ford Health System, Detroit, Michigan, USA
- 5International Agency for Research on Cancer, Lyon, France
- 6Campaign for Tobacco-Free Kids, Washington, DC, USA
- 7Pinney Associates, Inc, Bethesda, Maryland, USA
- Correspondence to: Jack E Henningfield PhD Pinney Associates, Inc, 4800 Montgomery Lane, Suite 1000, Bethesda, MD 20814, USA; jhenningpinneyassociates.com
Abstract
Tobacco product regulation has the potential to help reduce tobacco attributable disease by reducing the toxicity of these products and by reducing the prevalence of tobacco use and addiction
- FCTC, Framework Convention on Tobacco Control
- FDA, Food and Drug Administration
- FTC, Federal Trade Commission
- ISO, International Organization for Standardization
Footnotes
-
↵* In the present article we follow the convention1218 of using the term “addiction” in place of the more technical term “dependence”, which can also include “withdrawal” as defined by the WHO (1992—ICD10) and American Psychiatric Association.19 We note that the risk of the development and persistence of addiction, which contribute to addiction prevalence, is related to pharmacological factors, technically referred to as abuse liability,20 as well as factors affecting the acceptability of the formulation, ease of dosing, access, and marketing.12132122 Regulation could exert control over all of these contributors to addiction risk and prevalence; however, the present commentary is focused on characteristics of the product that contribute to its addiction risk and addiction prevalence.
